Sign in

CIK 0001601830

  • Large accelerated filer

RECURSION PHARMACEUTICALS, INC.

Sign in to watch
Ticker
RXRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464099738
Phone
+1 385-269-0203
Business address
41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
Former names
Recursion Pharmaceuticals, LLC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$701,222
in 5 filings, $701K under 10b5-1 plans

Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2024-10-24 Marriott Tina President and COO Sale 10b5-1 −6,000 $6.31 $38K 521,138
2024-10-24 Marriott Tina President and COO Exercise or conversion · Stock Option (Right to Buy) 10b5-1 −6,000 452,000
2024-10-15 Borgeson Blake Director Sale 10b5-1 −11,447 $6.67 $76K 7,089,007
2024-10-09 Secora Michael Chief Financial Officer Exercise or conversion 10b5-1 +39,375 $2.22 $87K 1,465,881
2024-10-09 Secora Michael Chief Financial Officer Sale 10b5-1 −15,000 $6.36 $95K 1,450,881
2024-10-09 Secora Michael Chief Financial Officer Exercise or conversion · Stock Option (Right to Buy) 10b5-1 −39,375 416,385
2024-10-08 Secora Michael Chief Financial Officer Exercise or conversion 10b5-1 +39,375 $2.22 $87K 1,441,506
2024-10-08 Secora Michael Chief Financial Officer Sale 10b5-1 −15,000 $6.32 $95K 1,426,506
2024-10-08 Secora Michael Chief Financial Officer Exercise or conversion · Stock Option (Right to Buy) 10b5-1 −39,375 455,760
2024-10-03 Gibson Christopher Chief Executive Officer Conversion 10b5-1 +20,000 782,656
2024-10-03 Gibson Christopher Chief Executive Officer Sale 10b5-1 −20,000 $6.08 $122K 762,656
2024-10-03 Gibson Christopher Chief Executive Officer Conversion · Class B Common Stock 10b5-1 −20,000 6,096,700
2024-10-02 Gibson Christopher Chief Executive Officer Conversion 10b5-1 +20,000 782,656
2024-10-02 Gibson Christopher Chief Executive Officer Sale 10b5-1 −20,000 $6.16 $123K 762,656
2024-10-02 Gibson Christopher Chief Executive Officer Conversion · Class B Common Stock 10b5-1 −20,000 6,116,700
2024-10-01 Borgeson Blake Director Grant or award +2,026 7,100,454
2024-10-01 Dar Zavain Director Grant or award +2,229 106,225
2024-10-01 Li Dean Y Director Grant or award +1,925 75,703
2024-10-01 Borgeson Blake Director Sale 10b5-1 −11,447 $6.22 $71K 7,098,428
2024-09-26 Marriott Tina President and COO Exercise or conversion 10b5-1 +6,000 $1.06 $6K 527,138

Page 14 of 41 · 805 trades